Nevro (NYSE: NVRO) is a public multinational medical technology company headquartered in Redwood City, California. We have developed HF10™ therapy, an innovative, evidence-based neuromodulation platform.
We started with a simple mission to help more patients suffering from chronic pain. At each stage of development, our research was subject to the highest levels of scientific rigor, resulting in a new therapy that has impacted the lives of over 28,000 patients around the world.
The Nevro® Senza® SCS System received CE mark in 2010, TGA approval in 2011, FDA approval in 2015, and is commercially available in Europe, Australia, and the United States.
The QA Compliance Intern shall work cross-functionally to review events and complaints as set forth by the FDA and other regulatory agencies. Requires internal and external follow-up to assure complete and accurate event files, complaint detail, and product performance information. Intern may also be asked to help with initial failure analysis of complaints based on experience.